Progyny (PGNY) Stock Price, News & Analysis

Company Overview

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Key Stats

• Today's Range: $23.17 to $23.88
• 50-Day Range: $20.79 to $24.27
• 52-Week Range: $13.39 to $26.76
• Volume: 630,374 shs
• Average Volume: 1.40 million shs
• Market Capitalization: $2.03 billion
• P/E Ratio: 40.12
• Dividend Yield: N/A
• Price Target: $25.30
• Consensus Rating: Moderate Buy

Progyny Stock Analysis - MarketRank™

Progyny scored higher than 54% of companies evaluated by MarketBeat, and ranked 630th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Progyny has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 6 buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Progyny has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 8.33%

Earnings Growth

Earnings for Progyny are expected to grow by 8.33% in the coming year, from $0.60 to $0.65 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Progyny is 40.12, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 53.99.

Price to Earnings Ratio vs. Sector

The P/E ratio of Progyny is 40.12, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 31.44.

Price to Earnings Growth Ratio

Progyny has a PEG Ratio of 1.88. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Progyny has a P/B Ratio of 3.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.89% of the float of Progyny has been sold short.

Short Interest Ratio / Days to Cover

Progyny has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in Progyny has recently decreased by 1.52%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Progyny does not currently pay a dividend.

Dividend Growth

Progyny does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.89% of the float of Progyny has been sold short.

Short Interest Ratio / Days to Cover

Progyny has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in Progyny has recently decreased by 1.52%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.23

News Sentiment

Progyny has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Progyny this week, compared to 8 articles on an average week.

MarketBeat Follows

3 people have added Progyny to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Progyny insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $114,137.00 in company stock.

Percentage Held by Insiders

Only 9.40% of the stock of Progyny is held by insiders.

Percentage Held by Institutions

94.93% of the stock of Progyny is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PGNY Stock Analysis - Frequently Asked Questions

How have PGNY shares performed this year?

Progyny's stock was trading at $17.25 at the beginning of 2025. Since then, PGNY shares have increased by 37.2% and is now trading at $23.6680.

How were Progyny's earnings last quarter?

Progyny, Inc. (NASDAQ:PGNY) released its quarterly earnings data on Thursday, August, 7th. The company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.42 by $0.23. Progyny's quarterly revenue was up 9.5% compared to the same quarter last year.
Read the conference call transcript.

When did Progyny IPO?

Progyny (PGNY) raised $150 million in an IPO on Friday, October 25th 2019. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers.

Who are Progyny's major shareholders?

Top institutional investors of Progyny include Thrivent Financial for Lutherans (5.69%), Ameriprise Financial Inc. (2.32%), Geode Capital Management LLC (2.03%) and Marshall Wace LLP (1.60%). Insiders that own company stock include Tpg Gp A, Llc, Peter Anevski, Michael E Sturmer, Norman Payson, David J Schlanger, Mark S Livingston, Cheryl Scott and Kevin K Gordon.
View institutional ownership trends.

How do I buy shares of Progyny?

Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Progyny own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Progyny investors own include Humana (HUM), American Water Works (AWK), NVIDIA (NVDA), Rambus (RMBS), Voyager Therapeutics (VYGR), Saia (SAIA) and Waste Connections (WCN).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 8/29/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:PGNY
• CIK: 1551306
• Web: www.progyny.com
• Phone: 212-888-3124
• Fax: N/A
• Employees: 310
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Progyny: $25.30
• High Price Target: $28.00
• Low Price Target: $17.00
• Potential Upside/Downside: +8.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.73
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.59
• Trailing P/E Ratio: 39.41
• Forward P/E Ratio: 38.75
• P/E Growth: 1.88
• Net Income: $54.34 million
• Net Margins: 4.28%
• Pretax Margin: 7.18%
• Return on Equity: 10.69%
• Return on Assets: 7.12%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.70
• Quick Ratio: 2.70

Sales & Book Value

• Annual Sales: $1.17 billion
• Price / Sales: 1.71
• Cash Flow: $0.35 per share
• Price / Cash Flow: 66.71
• Book Value: $5.99 per share
• Price / Book: 3.88

Miscellaneous

• Outstanding Shares: 85,980,000
• Free Float: 77,900,000
• Market Cap: $2.00 billion
• Optionable: Optionable
• Beta: 1.32